Moracizine

Moracizine

Clinical data
Trade names	Ethmozine
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a601214
Pregnancy category	B (U.S.)
ATC code	C01BG01 (WHO)
Pharmacokinetic data
Bioavailability	34–38%
Protein binding	95%
Elimination half-life	3–4 hours (healthy volunteers), 6–13 hours (cardiac disease)
Identifiers
IUPAC name ethyl [10-(3-morpholin-4-ylpropanoyl)-10H-phenothiazin-2-yl]carbamate
CAS Number	31883-05-3 Y
PubChem CID	34633
DrugBank	DB00680 N
ChemSpider	31872 Y
UNII	2GT1D0TMX1
KEGG	D05077 Y
ChEBI	CHEBI:6997 Y
ChEMBL	ChEMBL1075 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C22H25N3O4S
Molar mass	427.518 g/mol
3D model (JSmol)	Interactive image
SMILES O=C(OCC)Nc2cc1N(c3c(Sc1cc2)cccc3)C(=O)CCN4CCOCC4
InChI InChI=1S/C22H25N3O4S/c1-2-29-22(27)23-16-7-8-20-18(15-16)25(17-5-3-4-6-19(17)30-20)21(26)9-10-24-11-13-28-14-12-24/h3-8,15H,2,9-14H2,1H3,(H,23,27) Y Key:FUBVWMNBEHXPSU-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

WikiDoc Resources for Moracizine
Articles
Most recent articles on Moracizine Most cited articles on Moracizine Review articles on Moracizine Articles on Moracizine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Moracizine Images of Moracizine Photos of Moracizine Podcasts & MP3s on Moracizine Videos on Moracizine
Evidence Based Medicine
Cochrane Collaboration on Moracizine Bandolier on Moracizine TRIP on Moracizine
Clinical Trials
Ongoing Trials on Moracizine at Clinical Trials.gov Trial results on Moracizine Clinical Trials on Moracizine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Moracizine NICE Guidance on Moracizine NHS PRODIGY Guidance FDA on Moracizine CDC on Moracizine
Books
Books on Moracizine
News
Moracizine in the news Be alerted to news on Moracizine News trends on Moracizine
Commentary
Blogs on Moracizine
Definitions
Definitions of Moracizine
Patient Resources / Community
Patient resources on Moracizine Discussion groups on Moracizine Patient Handouts on Moracizine Directions to Hospitals Treating Moracizine Risk calculators and risk factors for Moracizine
Healthcare Provider Resources
Symptoms of Moracizine Causes & Risk Factors for Moracizine Diagnostic studies for Moracizine Treatment of Moracizine
Continuing Medical Education (CME)
CME Programs on Moracizine
International
Moracizine en Espanol Moracizine en Francais
Business
Moracizine in the Marketplace Patents on Moracizine
Experimental / Informatics
List of terms related to Moracizine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Moracizine (INN, or moricizine, trade name Ethmozine) is an antiarrhythmic of class IC. It was used for the prophylaxis and treatment of serious and life-threatening ventricular arrhythmias, but was withdrawn in 2007 for commercial reasons.

Pharmacology

Moracizine, a phenothiazine derivative, undergoes extensive first-pass metabolism and is also extensively metabolized after it has entered the circulation. It may have pharmacologically active metabolites. A clinical study has shown that moracizine is slightly less effective than encainide or flecainide in suppressing ventricular premature depolarizations. Compared with disopyramide and quinidine, moracizine was equally or more effective in suppressing premature ventricular contractions, couplets, and nonsustained ventricular tachycardia.

In the Cardiac Arrhythmia Suppression Trial (CAST), a large study testing the influence of antiarrhythmics on mortality, showed a non-significant increase of mortality from 5.4 to 7.2% under moracizine. This is in line with other class IC antiarrhythmics.